Godehard Oepen, MD
Psychiatry · Birmingham, ALNPI 1508811597
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $411,617 of the $515,834 with a category attached, or 79.8%. 25 manufacturers reported payments, led by AbbVie at 36.9% of the total. Reporting peaked in 2019 at $117,400 and has fallen 90.7% since, to $10,902 in 2025. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 842 payments — averaging $612.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$190K
- Teva Pharmaceuticals USA, Inc.$117K
- Otsuka America Pharmaceutical, Inc.$72K
- Axsome Therapeutics, Inc.$59K
- Alkermes, Inc.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- plus $14K from 19 others
What the payments were for
- Consulting fees$53,93810%
- Speaking & faculty fees$411,61780%
- Travel & lodging$34,7177%
- Food & beverage$15,3113%
- Education$2510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 276 | $190,343 |
| Teva Pharmaceuticals USA, Inc. | 152 | $117,181 |
| Otsuka America Pharmaceutical, Inc. | 100 | $71,602 |
| Axsome Therapeutics, Inc. | 56 | $58,627 |
| Alkermes, Inc. | 69 | $46,476 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $18,087 |
| Vanda Pharmaceuticals Inc. | 13 | $9,370 |
| Johnson & Johnson | 26 | $1,003 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 44 | $897 |
| Supernus Pharmaceuticals, Inc. | 5 | $583 |
| Lundbeck LLC | 14 | $313 |
| Neurocrine Biosciences, Inc. | 6 | $235 |
| Jazz Pharmaceuticals Inc. | 5 | $201 |
| Avanir Pharmaceuticals, Inc. | 5 | $196 |
| Sunovion Pharmaceuticals Inc. | 14 | $154 |
| Bausch Health US, LLC | 6 | $103 |
| Neuronetics, Inc. | 1 | $102 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $84 |
| Almatica Pharma LLC | 4 | $83 |
| Eisai Inc. | 5 | $69 |
| Indivior Inc. | 2 | $49 |
| Merck | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $21 |
| Adlon Therapeutics L.p. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$186,236
- LYBALVI$178,346
- AUSTEDO$81,547
- Auvelity$57,572
- REXULTI$40,348
- Austedo XR$33,682
- ABILIFY MAINTENA$32,398
- TRINTELLIX$17,601
- Fanapt$9,082
- ARISTADA$2,429
- ARISTADA INITIO$607
- INVEGA SUSTENNA$243
- SPRAVATO$232
- CAPLYTA$223
- NUEDEXTA$125
- VIVITROL$125
- INVEGA TRINZA$122
- NEUROSTAR TMS THERAPY$102
How this compares
$515,834 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 26 | $172,921 |
| TrintellixVortioxetine Hydrobromide | 126 | $61,877 |
| VraylarCariprazine Hcl | 33 | $48,805 |
| Aripiprazole | 188 | $9,601 |
| BelsomraSuvorexant | 12 | $6,328 |
| Bupropion XlBupropion Hcl | 270 | $5,284 |
| Lurasidone Hcl | 39 | $4,380 |
| Trazodone Hcl | 257 | $3,659 |
| Dextroamphetamine Sulfate | 11 | $3,173 |
| Quetiapine Fumarate | 149 | $2,289 |
| Lamotrigine | 192 | $1,915 |
| Clonazepam | 313 | $1,823 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $1,756 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $1,509 |
| Propranolol Hcl | 69 | $1,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $117,181 | $174,15350 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18,087 | $61,877126 claims |
| AbbVieVraylar | $190,343 | $48,80533 claims |
| MerckBelsomra | $23 | $6,32812 claims |
| Almatica Pharma LLCSertraline Hcl | $83 | $58599 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Richard SheltonBirmingham$79K
- Melissa KarrhBirmingham$51K
- Matthew MacalusoBirmingham$49K
- Santosh PillaiBirmingham$28K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.